Navigation Links
Introducing the multi-tasking nanoparticle
Date:8/26/2014

(SACRAMENTO, Calif.) Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. Built on an easy-to-make polymer, these particles can be used as contrast agents to light up tumors for MRI and PET scans or deliver chemo and other therapies to destroy tumors. In addition, the particles are biocompatible and have shown no toxicity. The study was published online today in Nature Communications.

"These are amazingly useful particles," noted co-first author Yuanpei Li, a research faculty member in the Lam laboratory. "As a contrast agent, they make tumors easier to see on MRI and other scans. We can also use them as vehicles to deliver chemotherapy directly to tumors; apply light to make the nanoparticles release singlet oxygen (photodynamic therapy) or use a laser to heat them (photothermal therapy) all proven ways to destroy tumors."

Jessica Tucker, program director of Drug and Gene Delivery and Devices at the National Institute of Biomedical Imaging and Bioengineering, which is part of the National Institutes of Health, said the approach outlined in the study has the ability to combine both imaging and therapeutic applications in a single platform, which has been difficult to achieve, especially in an organic, and therefore biocompatible, vehicle.

"This is especially valuable in cancer treatment, where targeted treatment to tumor cells, and the reduction of lethal effects in normal cells, is so critical," she added.

Though not the first nanoparticles, these may be the most versatile. Other particles are good at some tasks but not others. Non-organic particles, such as quantum dots or gold-based materials, work well as diagnostic tools but have safety issues. Organic probes are biocompatible and can deliver drugs but lack imaging or phototherapy applications.

Built on a porphyrin/cholic acid polymer, the nanoparticles are simple to make and perform well in the body. Porphyrins are common organic compounds. Cholic acid is produced by the liver. The basic nanoparticles are 21 nanometers wide (a nanometer is one-billionth of a meter).

To further stabilize the particles, the researchers added the amino acid cysteine (creating CNPs), which prevents them from prematurely releasing their therapeutic payload when exposed to blood proteins and other barriers. At 32 nanometers, CNPs are ideally sized to penetrate tumors, accumulating among cancer cells while sparing healthy tissue.

In the study, the team tested the nanoparticles, both in vitro and in vivo, for a wide range of tasks. On the therapeutic side, CNPs effectively transported anti-cancer drugs, such as doxorubicin. Even when kept in blood for many hours, CNPs only released small amounts of the drug; however, when exposed to light or agents such as glutathione, they readily released their payloads. The ability to precisely control chemotherapy release inside tumors could greatly reduce toxicity. CNPs carrying doxorubicin provided excellent cancer control in animals, with minimal side effects.

CNPs also can be configured to respond to light, producing singlet oxygen, reactive molecules that destroy tumor cells. They can also generate heat when hit with laser light. Significantly, CNPs can perform either task when exposed to a single wavelength of light.

CNPs offer a number of advantages to enhance imaging. They readily chelate imaging agents and can remain in the body for long periods. In animal studies, CNPs congregated in tumors, making them easier to read on an MRI. Because CNPs accumulated in tumors, and not so much in normal tissue, they dramatically enhanced tumor contrast for MRI and may also be promising for PET-MRI scans.

This versatility provides multiple options for clinicians, as they mix and match applications.

"These particles can combine imaging and therapeutics," said Li. "We could potentially use them to simultaneously deliver treatment and monitor treatment efficacy."

"These particles can also be used as optical probes for image-guided surgery," said Lam. "In addition, they can be used as highly potent photosensitizing agents for intraoperative phototherapy."

While early results are promising, there is still a long way to go before CNPs can enter the clinic. The Lam lab and its collaborators will pursue preclinical studies and, if all goes well, proceed to human trials. In the meantime, the team is excited about these capabilities.

"This is the first nanoparticle to perform so many different jobs," said Li. "From delivering chemo, photodynamic and photothermal therapies to enhancing diagnostic imaging, it's the complete package."


'/>"/>

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. Introducing: MMTR Physiotherapy, MMTR Health Inc. Announces Name Change
2. Introducing GKhair's New Fast Blow Dry, Chicago Style Meet & Greet
3. Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw
4. Introducing a New Sand Wedge that Is Perfect for Taking Strokes off the Short Game, Courtesy of Black Magic’s Innovative Golf Wedge
5. Diet Doc Hormone Diets & Weight Loss Plans Introduces New Diet Plans for Parents, Introducing Weight Loss to Parents to Help their Children Avoid Breast Cancer
6. Gifts That Give Back: Introducing Pour le Monde 100% Natural Perfumes
7. Belly Scarf is Introducing New Ccolors for Belly Dancing Hip Scarves
8. Introducing The Make Your Own Authentic Detroit Style Pizza Gift Set
9. Introducing solid foods while continuing to breast feed could prevent child allergies
10. Heated Mouse: Introducing ValueRays® Executive Series Heated Computer Mice
11. Introducing The Zurich Collection by SIGVARIS: A Luxury Line of Graduated Compression Socks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain company ... Tina Howe joined the team, the Bill Howe brand was born and they began ... and giving back to the San Diego community in which they worked, lived and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: